These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 20097723

  • 1. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB.
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.
    Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, Boernsen KO, Waldmeier F.
    Drug Metab Dispos; 2008 Dec; 36(12):2523-38. PubMed ID: 18775980
    [Abstract] [Full Text] [Related]

  • 3. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE, Hagemann TM.
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [Abstract] [Full Text] [Related]

  • 4. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D.
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [Abstract] [Full Text] [Related]

  • 5. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.
    Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Séchaud R.
    J Clin Pharmacol; 2003 Jun; 43(6):565-72. PubMed ID: 12817519
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
    Maker GL, Siva B, Batty KT, Trengove RD, Ferrari P, Olynyk JK.
    Nephrology (Carlton); 2013 Mar; 18(3):188-93. PubMed ID: 23332024
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox: pharmacokinetics and clinical experience.
    Galanello R, Campus S, Origa R.
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
    [Abstract] [Full Text] [Related]

  • 8. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
    Miyazawa K, Ohyashiki K, Urabe A, Hata T, Nakao S, Ozawa K, Ishikawa T, Kato J, Tatsumi Y, Mori H, Kondo M, Taniguchi J, Tanii H, Rojkjaer L, Omine M.
    Int J Hematol; 2008 Jul; 88(1):73-81. PubMed ID: 18597054
    [Abstract] [Full Text] [Related]

  • 9. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 10. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH, Lu MY, Liao YM, Lin PC, Yang YL, Lin DT, Chiou SS, Jou ST, Lin KH, Chang TT.
    Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
    [Abstract] [Full Text] [Related]

  • 11. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 12. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D.
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [Abstract] [Full Text] [Related]

  • 13. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V, Neokleous N, Agapidou A, Economou M, Vetsiou E, Teli A, Perifanis V.
    Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
    [No Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
    Chandra J, Chaudhary H, Pemde H, Singh V, Dutta AK.
    Ann Trop Paediatr; 2011 Jan; 31(1):47-51. PubMed ID: 21262109
    [Abstract] [Full Text] [Related]

  • 15. Deferasirox for transfusion-related iron overload: a clinical review.
    Lindsey WT, Olin BR.
    Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human.
    Weiss HM, Fresneau M, Camenisch GP, Kretz O, Gross G.
    Drug Metab Dispos; 2006 Jun; 34(6):971-5. PubMed ID: 16531476
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R.
    Ann N Y Acad Sci; 2005 Jun; 1054():183-5. PubMed ID: 16339664
    [Abstract] [Full Text] [Related]

  • 19. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T, Deferasirox in Sickle Cell Investigators.
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [Abstract] [Full Text] [Related]

  • 20. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.